WASHINGTON - The Food and Drug Administration is weighing the benefits and risks of two experimental colon cancer screening tests that use DNA from a patient's stool to detect dangerous tumors and growths.
FDA scientists have questions about the accuracy and the real-world impact of the kits if they are approved. The agency posted its reviews of the tests from Epigenomics and Exact Sciences online, ahead of a two-day meeting that starts Wednesday.
Doctors have long used stool tests to look for hidden blood that can be a warning sign of tumors and precancerous polyps.
Both tests reviewed by the FDA were more accurate at detecting tumors and worrisome growths than the traditional blood stool test. However, both tests also returned more false positives, reporting growths when none were actually present.
Notice about comments:
The Post and Courier is pleased to offer readers the enhanced ability to comment on stories. Some of the comments may be reprinted elsewhere in the site or in the newspaper. We ask that you refrain from profanity, hate speech, personal comments and remarks that are off point.